Literature DB >> 1619006

A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly.

J Weeke1, S E Christensen, H Orskov, A Kaal, M M Pedersen, P Illum, A G Harris.   

Abstract

Fifteen acromegalic patients received four single doses of octreotide in random order (500 micrograms, 1000 micrograms, and 2000 micrograms applied intranasally and 100 micrograms given sc). Serum octreotide and GH data were subjected to pharmacokinetic analyses, and local nasal effects were evaluated by acoustic rhinometry. Average areas (+/- SEM) under the serum octreotide curves were: 2000 micrograms: 4597 +/- 536; 1000 micrograms: 1923 +/- 439; 500 micrograms: 957 +/- 168; and 100 micrograms sc: 896 +/- 81 micrograms.L-1.min (n = 13). The calculated relative availability was 27% +/- 0.03; 22% +/- 0.05; 22% +/- 0.03, respectively, for the three nasal doses. The rate of absorption after intranasally administered octreotide was greater than after sc application: t1/2 ka: 7.1 +/- 1.6; 7.9 +/- 1.6; 11.3 +/- 1.9, respectively, vs. 24.1 +/- 2.5 min, whereas the rates of disappearance were similar. GH suppression started immediately after application and reached minimum levels 1-2 h later. The average intervals during which serum GH was below 50% of preadministration values were: 2000 micrograms: 544 +/- 47; 1000 micrograms: 423 +/- 56; 500 micrograms: 289 +/- 52 vs. 351 +/- 34 min after sc injection of 100 micrograms. With 2000 micrograms intranasally all but one of the 15 patients attained constant suppression of serum GH below 5 micrograms/L for 273 to 680 min. Pharmacokinetic analysis demonstrated that 100 micrograms sc and 1000 micrograms intranasally induced the same GH suppressive effect and that 2000 micrograms intranasally approximately doubled the duration of action. Acoustic rhinometry was performed after nasal application of the largest dose of 2000 micrograms and after carrier (n = 9). A highly significant tumescence of the nasal mucosa was maximal after 10 min and gradually receded over the next 2 h. However, this was felt by the patients to be acceptable. The effect was caused by octreotide per se and was probably due to vasodilation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1619006     DOI: 10.1210/jcem.75.1.1619006

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option.

Authors:  Asa Peterson; Amy Bansal; Florence Hofman; Thomas C Chen; Gabriel Zada
Journal:  J Neurooncol       Date:  2014-01-08       Impact factor: 4.130

Review 2.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

3.  In vitro tolerability of human nasal mucosa: histopathological and scanning electron-microscopic evaluation of nasal forms containing Sandostatin.

Authors:  A de Fraissinette; M Kolopp; I Schiller; G Fricker; C Gammert; A Pospischil; J Vonderscher; F Richter
Journal:  Cell Biol Toxicol       Date:  1995-10       Impact factor: 6.691

Review 4.  The Future of Somatostatin Receptor Ligands in Acromegaly.

Authors:  Monica R Gadelha; Luiz Eduardo Wildemberg; Leandro Kasuki
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

Review 5.  Current and Emerging Medical Therapies in Pituitary Tumors.

Authors:  Nicolas Sahakian; Frédéric Castinetti; Thierry Brue; Thomas Cuny
Journal:  J Clin Med       Date:  2022-02-12       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.